Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
NCT04348448
·
clinicaltrials.gov ↗
TERMINATED
Status
100
Enrollment
OTHER
Sponsor class
Stopped
due to covid
Conditions
COVID-19
Interventions
DRUG:
Canakinumab 150 MG/ML [Ilaris]
Sponsor
AUSL Romagna Rimini